https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17080 Wed 11 Apr 2018 16:38:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6870 Wed 11 Apr 2018 16:20:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19681 Wed 11 Apr 2018 14:42:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9232 Wed 11 Apr 2018 13:10:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14803 Wed 11 Apr 2018 13:00:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25542 Wed 11 Apr 2018 11:47:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22672 Wed 11 Apr 2018 10:11:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49324 Tue 14 Nov 2023 14:39:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37944 Tue 11 Oct 2022 17:29:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30811 12 weeks post-treatment). Results: Among 93 people treated, 59% had recently injected drugs (past month), 77% were receiving OST and 56% injected drugs during therapy. Overall, 76% completed treatment. Mean on-treatment adherence to PEG-IFN and ribavirin were 98.2% and 94.6%. Overall, 6% of participants missed >1 dose of PEG-IFN and 31% took <95% of their prescribed ribavirin., Higher treatment completion was observed among those receiving 12 vs. 24 weeks of treatment (97% vs. 46%, P < 0.001) while the proportion of participants with 95% on-treatment ribavirin adherence was similar between groups (67% vs. 72%, P = 0.664). Receiving 12 weeks of therapy was independently associated with treatment completion. No factors were associated with 95% RBV adherence. Neither recent injecting drug use at baseline nor during therapy was associated with treatment completion or adherence to ribavirin. In adjusted analysis, treatment completion was associated with SVR (aOR 23.9, 95% CI 2.9–193.8). Conclusions: This study demonstrated a high adherence to directly observed PEG-IFN and self-administered ribavirin among people with ongoing injecting drug use or receiving OST. These data also suggest that shortening therapy from 24 to 12 weeks can lead to improved treatment completion. Treatment completion was associated with improved response to therapy.]]> Thu 28 Oct 2021 13:03:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49345 Thu 11 May 2023 16:10:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42833 Thu 04 May 2023 15:13:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54694 Fri 08 Mar 2024 11:59:16 AEDT ]]>